The credit goes to all the healthcare professionals, patients and regulatory authorities that have contributed to the studies of Hanbeitai. Wenjie Zhang, Chairman, Executive Director, and CEO of Henlius, said, "We are excited to have Hanbeitai get approved as our fourth product.
The pipeline has been further replenished with widened indication coverage including hematological malignancies, solid tumors, auto-immune diseases, etc. Hanbeitai is the company's fourth monoclonal antibody (mAb) approved in China, following rituximab biosimilar Hanlikang, trastuzumab biosimilar Hanquyou (Zercepac Ⓡ in the EU), and adalimumab biosimilar Handayuan. It is indicated for the treatment of metastatic colorectal cancer (mCRC) and unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC). (2696.HK) announced that bevacizumab biosimilar Hanbeitai, developed and manufactured by Henlius independently, has been approved by the National Medical Products Administration (NMPA).
SHANGHAI, China I DecemI Shanghai Henlius Biotech, Inc.
0 kommentar(er)
